Bengal Physician Journal

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  12 (2025)
Volume  11 (2024)
Volume  10 (2023)
Volume  9 (2022)
Volume  8 (2021)
Volume  7 (2020)
Volume  6 (2019)
Volume  5 (2018)
Related articles

VOLUME 12 , ISSUE 1 ( January-March, 2025 ) > List of Articles

ORIGINAL RESEARCH

Serum Cystatin C in the Diagnosis of Early DN and Its Comparison with UACR: A Cross-sectional Observational Study

Praveen K Malik, Abhishek, Deepali Kaushik, Anjali

Keywords : Cystatin C, Diabetes mellitus, Diabetic nephropathy, Urinary albumin-to-creatinine ratio

Citation Information : Malik PK, Abhishek, Kaushik D, Anjali. Serum Cystatin C in the Diagnosis of Early DN and Its Comparison with UACR: A Cross-sectional Observational Study. Bengal Physician Journal 2025; 12 (1):24-28.

DOI: 10.5005/jp-journals-10070-8087

License: CC BY-NC 4.0

Published Online: 20-03-2025

Copyright Statement:  Copyright © 2025; The Author(s).


Abstract

Introduction: In India, diabetic nephropathy (DN) constitutes approximately 46% of chronic renal diseases in the elderly population, becoming the primary cause of end-stage renal disease (ESRD). Early detection of DN enables timely intervention and prevents progression to ESRD. Aim of study: To study serum cystatin C as a biomarker of early DN in comparison with urinary albumin-to-creatinine ratio (UACR). Materials and methods: This cross-sectional observational study was conducted in the Department of General Medicine of Employees’ State Insurance Corporation Medical College and Hospital, Faridabad, from 2021 to 2024 after obtaining clearance from our institutional ethical committee. The duration for the sample collection was 1 year. A total of 50 consenting diabetic patients who fulfilled the inclusion and exclusion criteria within the study period were included in the study. In diabetic patients with a glomerular filtration rate (GFR) of ≥30 mL/min/1.73 m2, indicating early DN (stages I, II, and III according to Mogensen's classification), serum cystatin C and UACR were assessed. We conducted a comparative analysis of serum cystatin C and the UACR as biomarkers for early DN. Results: Among 50 patients, 68% of the patients were aged between 41 and 50 years. The mean age was 43.06 ± 6.9 years. Among total subjects, 52% were males and 48% were females. The most common complaints were polyuria (56%), fatigue (56%), polydipsia (38%), and weight loss (34%). Mean values of diabetic parameters for fasting blood sugar (FBS), postprandial blood sugar (PBS), random blood sugar, and HbA1c were 224.82 ± 79.02 mg/dL, 341 ± 90.1 mg/dL, 331.56 ± 76.98 mg/dL, and 9.85 ± 2.37%, respectively. Mean duration of diabetes was 4.4 ± 3.48 years. About 30% of the cases were classified as stage I, 22% as stage II, and 48% as stage III. Serum cystatin C levels were elevated in 78% of cases. The mean serum cystatin C levels was 1.19 ± 0.39 mg/L, UACR was 95.22 ± 102.15 mg/gm, and GFR was 102.62 ± 28.54 mL/min/1.73 m2. Serum cystatin C levels showed a significant positive correlation with UACR with an r-value of 0.530 and significant p-value of < 0.001. Conclusion: This study suggests that serum cystatin C is a valuable biomarker for early detection of DN and its rise before the onset of microalbuminuria highlights its utility in clinical practice.

HTML PDF Share
  1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2014;37(1):S81−S90. DOI: 10.2337/dc14-S081.
  2. International Diabetes Federation. IDF diabetes atlas. 7th ed. Brussels (Belgium): International Diabetes Federation; 2015. p. 33.
  3. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia 1991;34:877–890. PMID: 1778353.
  4. Sharma RK. API textbook of medicine. 10th ed. Diabetes and kidney disease; vol. 1. New Delhi: Jaypee Brothers Medical Publisher; 2015. pp. 528−533.
  5. Fornoni A, Nelson RG, Najafian B, et al. Epidemiology of diabetic kidney disease. In: Yu ASL, Chertow GM, Luyckx VA, et al., editors. Brenner & Rector's The kidney. 11th ed. Canada: Elsevier; 2020. pp. 1332−1337.
  6. Jeon YK, Kim MR, Huh JE, et al. Cystatin C as an early biomarker of nephropathy in patients with type 2 diabetes. J Korean Med Sci 2011;26(2):258−263. DOI: 10.3346/jkms.2011.26.2.258.
  7. Ashok ML, Prashanth VN, Dudhewala A. Study of serum cystatin-C and its correlation with microalbuminuria as marker for diabetic nephropathy in a tertiary care hospital. Int J Basic Med Sci 2015;6(1):1−11.
  8. Sapkota S, Khatiwada S, Shrestha S, et al. Diagnostic accuracy of serum cystatin C for early recognition of nephropathy in type 2 diabetes mellitus. Int J Nephrol 2021;2021:8884126. DOI: 10.1155/2021/8884126.
  9. Chatterjee S, Khunti K, Davies MJ. Type 2 diabetes. Lancet 2017; 389(10085):2239−2251. DOI: 10.1016/S0140-6736(17)30058-2.
  10. Kautzky-Willer A, Harreiter J, Pacini G. Sex and gender differences in risk, pathophysiology and complications of type 2 diabetes mellitus. Endocrine Rev 2016;37(3):278−316. DOI: 10.1210/er.2015-1137.
  11. Mojiminiyi OA, Abdella N. Evaluation of cystatin C and β-2 microglobulin as markers of renal function in patients with type 2 diabetes mellitus. J Diabetes Complications 2003;17(3):160−168. DOI: 10.1016/s1056-8727(02)00177-0.
  12. Willi C, Bodenmann P, Ghali WA, et al. Active smoking and the risk of type 2 diabetes: A systematic review and meta-analysis. JAMA 2007;298(22):2654−2664. DOI: 10.1001/jama.298.22.2654.
  13. Pan A, Wang Y, Talaei M, et al. Relation of active, passive, and quitting smoking with incident type 2 diabetes: A systematic review and meta-analysis. Lancet Diabetes Endocrinol 2015;3(12):958−967. DOI: 10.1016/S2213-8587(15)00316-2.
  14. American Diabetes Association. 11. Microvascular complications and foot care: Standards of medical care in diabetes − 2019. Diabetes Care 2019;42(Suppl 1): S124–S138. DOI: 10.2337/dc19-S011.
  15. Cho Y, Park HS, Huh BW, et al. Prevalence and risk of diabetic complications in young-onset versus late-onset type 2 diabetes mellitus. Diabetes Metab 2022;48(6):101389. DOI: 10.1016/j.diabet.2022.101389.
  16. Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: Challenges, progress, and possibilities. Clin J Am Soc Nephrol 2017;12(12):2032−2045. DOI: 10.2215/CJN.11491116.
  17. Mussap M, Vestra MD, Fioretto P, et al. Cystatin C is a more sensitive marker than creatinine for the estimation of GFR in type 2 diabetic patients. Kidney Int 2002;61(4):1453−1461. DOI: 10.1046/j.1523-1755.2002.00253.x.
  18. Gupta K, Nayyar SB, Sachdeva J, et al. Cystatin C in the early diagnosis of diabetic nephropathy and its correlation with albuminuria. Int J Adv Med 2017;4(1):56−59. DOI: 10.18203/2349-3933.ijam20170020.
  19. Shohaib AA, Seleem AS, Barbary HE, et al. Evaluation of serum cystatin C as an indicator of early renal function decline in type 2 diabetes. Menoufia Med J 2014;27(1):60−65. DOI: 10.4103/1110-2098.132748.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.